VYNE Therapeutics (VYNE) Competitors $3.03 +0.13 (+4.48%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VYNE vs. NXTC, KZR, HOOK, PRTK, OGI, TSVT, ADAP, LFVN, ELDN, and HRTXShould you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include NextCure (NXTC), Kezar Life Sciences (KZR), Hookipa Pharma (HOOK), Paratek Pharmaceuticals (PRTK), Organigram (OGI), 2seventy bio (TSVT), Adaptimmune Therapeutics (ADAP), LifeVantage (LFVN), Eledon Pharmaceuticals (ELDN), and Heron Therapeutics (HRTX). These companies are all part of the "medical" sector. VYNE Therapeutics vs. NextCure Kezar Life Sciences Hookipa Pharma Paratek Pharmaceuticals Organigram 2seventy bio Adaptimmune Therapeutics LifeVantage Eledon Pharmaceuticals Heron Therapeutics NextCure (NASDAQ:NXTC) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends, community ranking and profitability. Does the MarketBeat Community favor NXTC or VYNE? NextCure received 50 more outperform votes than VYNE Therapeutics when rated by MarketBeat users. Likewise, 64.52% of users gave NextCure an outperform vote while only 63.83% of users gave VYNE Therapeutics an outperform vote. CompanyUnderperformOutperformNextCureOutperform Votes8064.52% Underperform Votes4435.48% VYNE TherapeuticsOutperform Votes3063.83% Underperform Votes1736.17% Which has more risk and volatility, NXTC or VYNE? NextCure has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Which has higher valuation and earnings, NXTC or VYNE? VYNE Therapeutics has higher revenue and earnings than NextCure. VYNE Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNextCureN/AN/A-$62.72M-$2.09-0.57VYNE Therapeutics$420K106.41-$28.45M-$0.86-3.52 Do analysts recommend NXTC or VYNE? NextCure currently has a consensus target price of $4.00, indicating a potential upside of 236.13%. VYNE Therapeutics has a consensus target price of $6.88, indicating a potential upside of 126.90%. Given NextCure's higher possible upside, analysts clearly believe NextCure is more favorable than VYNE Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00VYNE Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in NXTC or VYNE? 42.7% of NextCure shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 13.3% of NextCure shares are held by company insiders. Comparatively, 4.8% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is NXTC or VYNE more profitable? NextCure has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,896.55%. VYNE Therapeutics' return on equity of -43.73% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets NextCureN/A -62.50% -53.67% VYNE Therapeutics -6,896.55%-43.73%-38.55% Does the media favor NXTC or VYNE? In the previous week, VYNE Therapeutics had 4 more articles in the media than NextCure. MarketBeat recorded 5 mentions for VYNE Therapeutics and 1 mentions for NextCure. VYNE Therapeutics' average media sentiment score of 0.20 beat NextCure's score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VYNE Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryVYNE Therapeutics beats NextCure on 9 of the 15 factors compared between the two stocks. Ad Darwin2025: Digital Asset Insights You Need to KnowCryptocurrencies are taking off again, and those in-the-know are positioning themselves to ride this wave in 2025. The question is—will you be one of them? With explosive growth on the horizon, there’s never been a better time to understand the potential gains in crypto. Our guide, Navigating the Future: Cryptos to Watch in 2025, reveals the cryptos leading this surge and the strategies to maximize your profit potential.Get your guide today! Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYNE vs. The Competition Export to ExcelMetricVYNE TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.69M$7.00B$5.38B$8.84BDividend YieldN/A8.11%5.13%4.09%P/E Ratio-3.5211.01105.0417.81Price / Sales106.41361.871,235.79158.52Price / CashN/A52.5940.3536.29Price / Book0.7010.377.086.50Net Income-$28.45M$153.60M$119.58M$226.22M7 Day Performance12.22%4.59%2.25%4.03%1 Month Performance27.85%-6.28%-2.34%4.92%1 Year Performance-22.31%33.39%33.95%29.30% VYNE Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYNEVYNE Therapeutics2.547 of 5 stars$3.03+4.5%$6.88+126.9%-22.3%$44.69M$420,000.00-3.5230NXTCNextCure4.4032 of 5 stars$1.29-0.8%$4.00+210.1%-4.8%$36.13MN/A-0.6290KZRKezar Life Sciences4.471 of 5 stars$7.62+1.7%$40.50+431.5%-17.8%$55.63M$7M-0.5860HOOKHookipa Pharma2.2964 of 5 stars$2.30-15.4%$38.33+1,566.7%-56.7%$27.74M$20.13M-0.6856Analyst ForecastNews CoverageHigh Trading VolumePRTKParatek PharmaceuticalsN/A$2.23+1.8%N/A+0.0%$127.82M$160.27M-2.03268High Trading VolumeOGIOrganigram0.4567 of 5 stars$1.51+1.3%N/A+20.6%$163.93M$120.01M-3.52860TSVT2seventy bio2.3879 of 5 stars$3.16+1.6%$9.00+184.8%+107.5%$163.02M$100.39M-1.69440ADAPAdaptimmune Therapeutics2.1205 of 5 stars$0.63-4.5%$3.16+399.5%+47.3%$162.00M$60.28M-2.88449LFVNLifeVantage3.0517 of 5 stars$13.16+1.8%N/A+157.7%$161.95M$196.01M41.13260ELDNEledon Pharmaceuticals3.1423 of 5 stars$4.07+5.7%$16.00+293.1%+234.2%$161.42MN/A-2.0210Analyst ForecastAnalyst RevisionHRTXHeron Therapeutics4.006 of 5 stars$1.06-5.4%$5.67+434.6%-21.9%$161.23M$127.04M-5.89300Analyst Downgrade Related Companies and Tools Related Companies NXTC Competitors KZR Competitors HOOK Competitors PRTK Competitors OGI Competitors TSVT Competitors ADAP Competitors LFVN Competitors ELDN Competitors HRTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VYNE) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
